GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
Y

Yixintang Pharmaceutical Co 002727.SZ · CNY

Consumer Staples · Shenzhen · 🇨🇳 China

Compare

12.98

-3.71%

Close of 9 Nov 2026, in CNY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in CNY, from our data supplier.

FY2025

Revenue

CN¥17.34bn

FY2016FY2025

Net income

CN¥263.4m

FY2016FY2025

Free cash flow

CN¥1.36bn

FY2016FY2025

Shareholders' equity

CN¥7.30bn

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
RevenueCN¥17.34bnCN¥18.00bnCN¥17.38bnCN¥17.43bnCN¥14.59bnCN¥12.66bnCN¥10.48bnCN¥9.18bnCN¥7.75bnCN¥6.25bn
Gross profitCN¥5.66bnCN¥5.57bnCN¥5.58bnCN¥5.95bnCN¥5.27bnCN¥4.45bnCN¥3.99bnCN¥3.64bnCN¥3.12bnCN¥2.51bn
Research and developmentCN¥10.6mCN¥9.7mCN¥10.2mCN¥8.7mCN¥5.4mCN¥839,485CN¥238,511CN¥146,388CN¥146,388CN¥146,388
Operating incomeCN¥745.4mCN¥278.0mCN¥786.4mCN¥1.24bnCN¥1.24bnCN¥984.9mCN¥788.8mCN¥745.4mCN¥613.0mCN¥454.2m
Net incomeCN¥263.4mCN¥114.1mCN¥549.4mCN¥1.01bnCN¥921.6mCN¥790.0mCN¥603.9mCN¥521.1mCN¥422.7mCN¥353.4m
Diluted earnings per share0.450.200.911.691.561.351.060.920.810.68

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assetsCN¥15.61bnCN¥16.83bnCN¥16.65bnCN¥16.18bnCN¥14.34bnCN¥9.33bnCN¥7.96bnCN¥7.36bnCN¥7.15bnCN¥6.01bn
Cash and short-term investments—CN¥3.42bnCN¥3.90bnCN¥3.52bnCN¥2.53bnCN¥1.62bnCN¥1.46bnCN¥1.35bnCN¥2.20bnCN¥1.59bn
Total liabilitiesCN¥8.15bnCN¥9.18bnCN¥8.77bnCN¥8.65bnCN¥7.66bnCN¥3.55bnCN¥3.37bnCN¥3.31bnCN¥3.45bnCN¥3.52bn
Debt—CN¥2.03bnCN¥2.02bnCN¥3.09bnCN¥2.91bnCN¥60.1mCN¥482.8mCN¥798.9mCN¥896.5mCN¥794.9m
Shareholders' equityCN¥7.30bnCN¥7.49bnCN¥7.75bnCN¥7.43bnCN¥6.58bnCN¥5.77bnCN¥4.59bnCN¥4.05bnCN¥3.69bnCN¥2.50bn
Shares outstanding585m581m604m599m593m586m568m568m521m521m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operationsCN¥1.63bnCN¥1.72bnCN¥2.12bnCN¥2.50bnCN¥1.79bnCN¥1.03bnCN¥982.9mCN¥635.8mCN¥391.2mCN¥192.6m
Capital spending−CN¥278.3m−CN¥254.8m−CN¥253.5m−CN¥349.0m−CN¥391.6m−CN¥280.2m−CN¥206.9m−CN¥156.0m−CN¥142.0m−CN¥146.1m
Free cash flowCN¥1.36bnCN¥1.47bnCN¥1.86bnCN¥2.15bnCN¥1.40bnCN¥753.2mCN¥776.1mCN¥479.7mCN¥249.1mCN¥46.5m
Dividends paid−CN¥304.9m−CN¥260.5m−CN¥238.4m−CN¥178.9m−CN¥178.9m−CN¥170.3m−CN¥170.3m−CN¥211.6m−CN¥168.5m−CN¥133.9m

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
RevenueCN¥4.03bnCN¥4.43bnCN¥4.34bnCN¥4.09bnCN¥4.15bnCN¥4.77bnCN¥4.41bnCN¥4.28bn
Gross profitCN¥1.35bnCN¥1.47bnCN¥1.44bnCN¥1.38bnCN¥1.32bnCN¥1.52bnCN¥1.26bnCN¥1.46bn
Operating incomeCN¥151.9mCN¥281.6mCN¥186.5mCN¥47.0mCN¥121.0mCN¥203.5m−CN¥129.5mCN¥42.8m
Net incomeCN¥81.0mCN¥175.8m−CN¥5.2mCN¥18.9mCN¥89.6mCN¥160.1m−CN¥178.4mCN¥10.6m
Diluted earnings per share0.140.30-0.010.030.150.27-0.310.02
Cash from operations———CN¥527.0mCN¥414.0mCN¥490.0m—CN¥319.0m
Capital spending−CN¥58.0m−CN¥85.0m−CN¥85.0m−CN¥61.0m−CN¥40.0m−CN¥91.0m−CN¥86.0m−CN¥67.0m
Free cash flow———CN¥466.0mCN¥374.0mCN¥399.0m—CN¥252.0m
Total assetsCN¥15.31bnCN¥15.69bnCN¥15.61bnCN¥15.84bnCN¥16.16bnCN¥16.95bnCN¥16.83bnCN¥17.13bn
Cash and short-term investments———CN¥3.20bnCN¥3.24bnCN¥3.45bnCN¥3.42bnCN¥3.24bn
DebtCN¥8.8m——CN¥3.06bnCN¥671.3mCN¥684.9mCN¥495.6mCN¥495.5m
Shareholders' equityCN¥7.45bnCN¥7.48bnCN¥7.30bnCN¥7.32bnCN¥7.42bnCN¥7.50bnCN¥7.49bnCN¥7.69bn

Financial ratios

Data as of 9 Oct 2026

FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Gross margin32.6%31.0%32.1%34.1%36.1%35.1%—
Operating margin3.1%2.0%4.8%8.0%8.5%7.8%—
Net margin1.5%0.6%3.2%5.8%6.3%6.2%—
Return on equity3.6%1.5%7.1%13.6%14.0%13.7%—
Return on assets1.7%0.7%3.3%6.2%6.4%8.5%—
Free cash flow yield29.7%30.9%35.7%43.3%33.5%20.4%—
Revenue growth-3.7%3.6%-0.3%19.5%15.3%20.8%—
Earnings growth130.8%-79.2%-45.6%9.6%16.7%30.8%—
Current ratio1.30x1.27x1.37x1.38x1.31x1.90x—
Debt to equity—0.07x0.06x0.05x0.02x-0.26x0.11x
Equity ratio46.8%44.5%46.5%45.9%45.9%61.8%—
Interest coverage4.05x2.37x6.03x9.17x8.83x35.20x—
R&D as a share of sales0.1%0.1%0.1%0.1%0.0%0.0%—
Buybacks as a share of market value-0.7%3.7%-0.9%-1.0%-1.1%-3.2%—

Growth per year

Compound annual rate

3 years5 years10 years
Revenue-0.2%6.5%12.5%
Operating income-15.7%-5.4%7.0%
Net income-36.1%-19.7%-2.7%

Average margins

Over each period

1 year3 years5 years10 years
Gross margin31.8%32.4%33.3%35.1%
Operating margin2.9%4.4%5.4%6.1%
Net margin1.1%2.8%3.7%4.3%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings28.666.325.418.724.824.721.919.424.831.2
Price to sales0.40.40.81.11.61.51.31.11.41.8

Dividends and splits

Per share, in the currency the company pays

Paid for 11 years. Last went ex-dividend on 25 Sept 2025.

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Paid in the year0.500.400.400.300.300.300.300.30
  • 2-for-1 split · 13 Apr 2016

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.